Health Care Equipment & Services

Fresenius SE’s Q1 2024 earnings show a modest profit rebound fueled by Kabi’s device sales and Helios’s cost‑effective hospital services, while a strategic SAP partnership and new AI‑driven venture fund aim to strengthen margins and future growth am…

Royal Philips NV beats Q1 expectations with stronger-than‑forecast operating income, cost control, and a clear focus on AI‑enabled imaging, patient monitoring and cloud‑health solutions for future growth.

Demant’s Q1 2026 revenue beats expectations thanks to the premium Oticon Zeal, acquisitions, and cost‑saving plans—boosting margins and positioning the company for growth amid rising AI‑driven competition.

ResMed’s institutional and executive holdings reveal strong mid‑cap stability, while regulatory and competitive shifts hint at future growth risks and opportunities.

Siemens Healthineers reports Q1 2026 earnings growth, expanding cloud‑based solutions and advanced diagnostic platforms, reinforcing its lead in digital health.

Fresenius SE & Co. KGaA’s Q1 2026 results show steady biopharma, medical tech, and hospital growth, with a 5‑10% EPS lift, AI‑driven digitalisation, and capital‑efficiency focus.

Fresenius SE & Co. KGaA’s Q1‑2026 performance shows robust margins and organic growth, but regulatory shifts, FMC’s US volume decline and digital risks could challenge future earnings. Explore the insights.

Veeva’s May 2026 filings reveal board confidence, a $2 billion share‑buyback, and new governance moves as the company hits the S&P 500, boosting investor trust and positioning in life‑science cloud tech.

Explore ResMed’s latest executive changes, ETF inclusion, and analyst focus—key insights into its governance, market stance, and future outlook.

Labcorp’s Q1 2026 earnings show steady 2 % revenue growth, solid gross margins and disciplined SG&A, positioning the lab giant for AI‑driven diagnostics and value‑based reimbursement success.